The Latest Breaking News from Veracyte

Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

A Relative Strength Rating upgrade for Veracyte shows improving technical performance.

The Dow and S&P 500 are near all-time highs early Friday as Apple stock flashes a buy signal. Deckers and Atlassian diverged on earnings.

On Tuesday, Veracyte got an upgrade for its IBD SmartSelect Composite Rating from 92 to 96.

9 analysts have expressed a variety of opinions on Veracyte (NASDAQ:VCYT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Veracyte (VCYT) exceeded Wall Street’s expectations in its first-quarter earnings report and is well-positioned to capitalize on the expanding genomic diagnostics market. However, with its stretched valuation and increased volatility, is VCYT a smart investment? Read on to find out….

Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Veracyte (NASDAQ:VCYT) brought in sales totaling $67.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 37.36%, resulting in a loss of $14.46 million.